Breast Cancer Test Links Immune Hotspots to Better Survival
|
By LabMedica International staff writers Posted on 15 Mar 2015 |
A new test has been developed that can predict the survival chances of women with breast cancer by analyzing images of hotspots where there has been an intense immune reaction to a tumor.
The test that combines automated histological image processing with methods of spatial statistics could assess whether a woman's immune system is holding a cancer at bay and pick out those who will need intensive treatment to combat their more aggressive disease.
Scientists at The Institute of Cancer Research (London, UK) and their colleagues analyzed tumor samples from 245 women with a type of breast cancer called estrogen receptor negative (ER negative), which is particularly hard to treat. The team split women with breast cancer into two groups based on the numbers of immune hotspots spots within their tumors.
The tumor sections were scanned using ScanScope TX Scanner (Aperio Technologies; Vista, CA, USA) with × 20 magnification and digitized for image analysis. Stained frozen tumor section images for 245 ER-negative breast cancer patients were analyzed using their automated cell classification pipeline CRImage. The cell classification and location data were used as input for Getis–Ord hotspot analysis to enable the automated detection of statistically significant spatial clusters.
The scientists found that images of hotspots where immune cells were spatially clustered together around breast cancer cells provided a better measure of immune response than simply the numbers of immune cells within a tumor. Women whose cancers had a high number of spots lived an average of 91 months before their cancer spread, compared with just 64 months for those with a low number of spots. The test is the first objective method of measuring the strength of a patient's immune response to their tumors. Its automated analysis could complement existing methods where pathologists examine tumor samples under the microscope to gain a sense of whether there is a strong immune response.
Yinyin Yuan, PhD, the team leader and senior author, said, “We have shown that to measure the strength of an immune response to a cancer, we need to assess not just how many immune cells there are, but whether these are clustered together into cancer-busting hotspots. By analyzing the complex ways in which the immune system interacts with cancer cells, we can split women with breast cancer into two groups, who might need different types of treatment.” The study was published on February 27, 2015, in the journal Modern Pathology.
Related Links:
The Institute of Cancer Research
Aperio Technologies
The test that combines automated histological image processing with methods of spatial statistics could assess whether a woman's immune system is holding a cancer at bay and pick out those who will need intensive treatment to combat their more aggressive disease.
Scientists at The Institute of Cancer Research (London, UK) and their colleagues analyzed tumor samples from 245 women with a type of breast cancer called estrogen receptor negative (ER negative), which is particularly hard to treat. The team split women with breast cancer into two groups based on the numbers of immune hotspots spots within their tumors.
The tumor sections were scanned using ScanScope TX Scanner (Aperio Technologies; Vista, CA, USA) with × 20 magnification and digitized for image analysis. Stained frozen tumor section images for 245 ER-negative breast cancer patients were analyzed using their automated cell classification pipeline CRImage. The cell classification and location data were used as input for Getis–Ord hotspot analysis to enable the automated detection of statistically significant spatial clusters.
The scientists found that images of hotspots where immune cells were spatially clustered together around breast cancer cells provided a better measure of immune response than simply the numbers of immune cells within a tumor. Women whose cancers had a high number of spots lived an average of 91 months before their cancer spread, compared with just 64 months for those with a low number of spots. The test is the first objective method of measuring the strength of a patient's immune response to their tumors. Its automated analysis could complement existing methods where pathologists examine tumor samples under the microscope to gain a sense of whether there is a strong immune response.
Yinyin Yuan, PhD, the team leader and senior author, said, “We have shown that to measure the strength of an immune response to a cancer, we need to assess not just how many immune cells there are, but whether these are clustered together into cancer-busting hotspots. By analyzing the complex ways in which the immune system interacts with cancer cells, we can split women with breast cancer into two groups, who might need different types of treatment.” The study was published on February 27, 2015, in the journal Modern Pathology.
Related Links:
The Institute of Cancer Research
Aperio Technologies
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
- Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
- Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
- Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
- Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
- AI Tool Improves Breast Cancer Detection
- AI Tool Predicts Treatment Success in Rectal Cancer Patients
- Blood Test and Sputum Analysis Predict Acute COPD Exacerbation
- AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
- Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
- Simple Optical Microscopy Method Reveals Hidden Structures in Remarkable Detail
- Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Blood Test Enables Non-Invasive Endometriosis Detection
Endometriosis is a chronic, complex, yet relatively common gynecological disorder, reportedly affecting 1 in 10 adult and adolescent women. Endometriosis causes tissue similar to the lining of the uterus... Read more
New Blood Biomarkers Help Diagnose Pregnancy-Linked Liver Complication
Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder linked to pregnancy and can pose serious risks for both mother and baby, including premature delivery and stillbirth.... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
Lower-respiratory tract infections (LRTIs) are a leading cause of illness and death worldwide, and pneumonia is the leading infectious cause of death in children under five, claiming the lives of over... Read more
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more





 assay.jpg)

 Analyzer.jpg)

